- Home
- XNCR vs SANA Comparison
XNCR vs SANA Comparison
Compare XNCR & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- SANA
- Stock Information
- Founded
- XNCR 1997
- SANA 2018
- Country
- XNCR United States
- SANA United States
- Employees
- XNCR N/A
- SANA N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- XNCR Health Care
- SANA Health Care
- Exchange
- XNCR Nasdaq
- SANA Nasdaq
- Market Cap
- XNCR 579.3M
- SANA 489.5M
- IPO Year
- XNCR 2013
- SANA 2021
- Fundamental
- Price
- XNCR $9.65
- SANA $2.84
- Analyst Decision
- XNCR Buy
- SANA Strong Buy
- Analyst Count
- XNCR 8
- SANA 5
- Target Price
- XNCR $29.29
- SANA $9.50
- AVG Volume (30 Days)
- XNCR 968.8K
- SANA 4.3M
- Earning Date
- XNCR 08-04-2025
- SANA 05-08-2025
- Dividend Yield
- XNCR N/A
- SANA N/A
- EPS Growth
- XNCR N/A
- SANA N/A
- EPS
- XNCR N/A
- SANA N/A
- Revenue
- XNCR $127,228,000.00
- SANA N/A
- Revenue This Year
- XNCR N/A
- SANA N/A
- Revenue Next Year
- XNCR $29.35
- SANA N/A
- P/E Ratio
- XNCR N/A
- SANA N/A
- Revenue Growth
- XNCR N/A
- SANA N/A
- 52 Week Low
- XNCR $7.16
- SANA $1.26
- 52 Week High
- XNCR $27.24
- SANA $7.89
- Technical
- Relative Strength Index (RSI)
- XNCR 59.62
- SANA 74.89
- Support Level
- XNCR $8.76
- SANA $2.26
- Resistance Level
- XNCR $9.60
- SANA $2.44
- Average True Range (ATR)
- XNCR 0.52
- SANA 0.24
- MACD
- XNCR 0.29
- SANA 0.08
- Stochastic Oscillator
- XNCR 90.87
- SANA 92.40
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.